SynVest Imaging Inc.
SynVest Imaging is developing a fluorine-18-labeled SV2A PET tracer for quantitative measurement of synaptic density. The company is at the preclinical and IND-enabling stage and identifies radiopharmacy distribution, clinical biomarker programs, and academic studies as collaboration areas.
Industries
N/A
Products
An investigational fluorine-18-labeled SV2A PET tracer intended for quantitative imaging of synaptic density. It is preclinical and not approved for clinical use.
An investigational fluorine-18-labeled SV2A PET tracer intended for quantitative imaging of synaptic density. It is preclinical and not approved for clinical use.
Services
Collaboration pathway for production and distribution of the fluorine-18-labeled tracer through radiopharmacy networks.
Use of SV2A PET as an imaging biomarker in pharmaceutical clinical programs.
Collaboration on investigator studies and cohort research using SV2A PET.
Collaboration pathway for production and distribution of the fluorine-18-labeled tracer through radiopharmacy networks.
Use of SV2A PET as an imaging biomarker in pharmaceutical clinical programs.
Collaboration on investigator studies and cohort research using SV2A PET.
Expertise Areas
- Molecular imaging
- PET imaging
- Neurodegenerative disease biomarkers
- Radiopharmaceutical development
Key Technologies
- SV2A-targeted PET imaging
- Fluorine-18 radiotracers
- Quantitative PET
- Radiopharmacy distribution
Key People
CEO & Director
CEO & Director
News & Updates
A U.S. composition-of-matter patent covering both molecules is reported as granted in 2022 and exclusively licensed to the company.
A U.S. composition-of-matter patent covering both molecules is reported as granted in 2022 and exclusively licensed to the company.